Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Non-Current Deferred Tax Liability: 2019-2024

Historic Non-Current Deferred Tax Liability for Pharming Group N.V (PHAR) over the last 6 years, with Dec 2024 value amounting to -$30.5 million.

  • Pharming Group N.V's Non-Current Deferred Tax Liability fell 2.63% to -$30.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$30.5 million, marking a year-over-year decrease of 2.63%. This contributed to the annual value of -$30.5 million for FY2024, which is 2.63% down from last year.
  • According to the latest figures from FY2024, Pharming Group N.V's Non-Current Deferred Tax Liability is -$30.5 million, which was down 2.63% from -$29.8 million recorded in FY2023.
  • In the past 5 years, Pharming Group N.V's Non-Current Deferred Tax Liability ranged from a high of -$21.2 million in FY2021 and a low of -$31.9 million during FY2020.
  • Over the past 3 years, Pharming Group N.V's median Non-Current Deferred Tax Liability value was -$29.8 million (recorded in 2023), while the average stood at -$27.8 million.
  • In the last 5 years, Pharming Group N.V's Non-Current Deferred Tax Liability spiked by 33.44% in 2021 and then decreased by 29.55% in 2023.
  • Pharming Group N.V's Non-Current Deferred Tax Liability (Yearly) stood at -$31.9 million in 2020, then skyrocketed by 33.44% to -$21.2 million in 2021, then declined by 8.28% to -$23.0 million in 2022, then dropped by 29.55% to -$29.8 million in 2023, then decreased by 2.63% to -$30.5 million in 2024.